Patents by Inventor BIJAN ANDRE BOLDAJIPOUR

BIJAN ANDRE BOLDAJIPOUR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric antigen receptors targeting B-cell maturation antigen
    Patent number: 11912776
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: February 27, 2024
    Assignee: PFIZER INC.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • ANTIBODIES HAVING CONDITIONAL AFFINITY AND METHODS OF USE THEREOF
    Publication number: 20230192839
    Abstract: Provided herein are antibodies with conditional affinity for an antigen. The affinity of an antibody with conditional affinity for an antigen may be altered by a small molecule agent. Antibodies with conditional affinity may be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Application
    Filed: March 29, 2018
    Publication date: June 22, 2023
    Applicant: PFIZER INC.
    Inventors: Bijan Andre BOLDAJIPOUR, Javier Fernando CHAPARRO RIGGERS, Xiaodi DENG, Kevin Charles LINDQUIST, Spencer PARK, Edward Derrick PASCUA, Thomas John VAN BLARCOM
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20220340671
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Application
    Filed: March 15, 2022
    Publication date: October 27, 2022
    Inventors: Tracy Chia-Chien KUO, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • Chimeric antigen receptors targeting B-cell maturation antigen
    Patent number: 11312782
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: April 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20190241669
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Inventors: Tracy Chia-Chien KUO, Bijan Andre BOLDAJIPOUR, Javier Fernando CHAPARRO RIGGERS, Philippe DUCHATEAU, Roman Ariel GALETTO, Alexandre JUILLERAT, Thomas Charles PERTEL, Arvind RAJPAL, Barbra Johnson SASU, Cesar Adolfo SOMMER, Julien VALTON, Thomas John VAN BLARCOM
  • Chimeric antigen receptors targeting B-cell maturation antigen
    Patent number: 10294304
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 21, 2019
    Assignee: Pfizer Inc.
    Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20160297884
    Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
    Type: Application
    Filed: March 30, 2016
    Publication date: October 13, 2016
    Inventors: TRACY CHIA-CHIEN KUO, BIJAN ANDRE BOLDAJIPOUR, JAVIER FERNANDO CHAPARRO RIGGERS, PHILIPPE DUCHATEAU, ROMAN GALETTO, ALEXANDRE JUILLERAT, THOMAS CHARLES PERTEL, ARVIND RAJPAL, BARBRA JOHNSON SASU, CESAR ADOLFO SOMMER, JULIEN VALTON, THOMAS JOHN VAN BLARCOM